CAN FITE BIOPHARMA LTD-ADR (CANF)

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023

CANF stock results show that Can Fite Biofarma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

PETACH TIKVA, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a...

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference

Can-Fite Biopharma discloses $100M mixed shelf offering - filing (NYSE:CANF)

Can-Fite Biopharma (CANF) disclosed in an SEC filing Friday that it plans to conduct a mixed shelf offering of securities worth up to $100 million.The company plans to offer...

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

Can-Fite to Present at the Emerging Growth Conference on July 13, 2023

Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients